Blog

The emergence of new drugs and therapies for early stage Alzheimer’s disease (AD), known as mild cognitive impairment (MCI) or mild dementia, has intensified the challenge of identifying the most appropriate, cost-effective treatment for (AD). The risk-benefit of these new disease modifying agents has raised urgency for accurate tests to verify an AD diagnosis earlier in the disease …

An estimated 5.8 million Americans age 65 and older live with Alzheimer’s disease (AD), a progressive disease that destroys memory and other important mental functions, with projections showing that by 2050 that number will reach 12.7 million.  AD tends to progress slowly in three general stages: early or mild cognitive impairment (MCI), moderate and severe. Because AD affects people in different ways, each person may experience …